NEW YORK (GenomeWeb News) – Trovagene said this week that it will collaborate with researchers at the University of Texas MD Anderson Cancer Center on detecting transrenal BRAF mutations in the urine of patients with advanced or metastatic cancers. The researchers will use Trovagene's transrenal DNA detection technology to evaluate BRAF mutation status in urine compared to tissue biopsy. The partners previously collaborated on detecting transrenal KRAS mutations in the urine of patients with pancreatic cancer.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Under a proposed spending bill, the US National Institutes of Health would see an additional $3 billion in funding.

Researchers from the University of Oxford and the University of Sydney sequenced numerous platypus genomes to study their population history.

Robert Redfield, the new pick to lead the US Centers for Disease Control and Prevention, has faced criticism for some of his work.

In Nature this week: sequenced genomes of five additional Neanderthals, and more.